JHOP Web Exclusives

The investigational chimeric antigen receptor (CAR) T-cell therapy KTE-C19 achieved complete responses that were durable for >1 year in more than 75% of patients with aggressive lymphomas who had no other effective treatment options, according to results from the phase 2 pivotal clinical trial ZUMA-1 that were presented by Sattva S. Neelapu, MD, Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center, at the 2016 American Society of Hematology meeting.
  • Rubraca Approved for Advanced Ovarian Cancer with BRCA Mutations
  • Avastin Approved for Platinum-Sensitive Ovarian Cancer
  • Darzalex Approved for Use in Combination with Standard Regimen for Multiple Myeloma
  • Opdivo Now Approved for Head and Neck Squamous-Cell Carcinoma
The American Society of Health-System Pharmacists (ASHP) Foundation's Pharmacy Forecast, now in its fourth edition, serves to improve the effectiveness of leaders in hospital and health-system pharmacy practice.
Page 5 of 5
Results 41 - 43 of 43